Thank you, operator, and a warm welcome to Bactiguard's third quarter presentation for 2026. I am joining you today from Boston. Following a couple of days at the AdvaMed MedTech Trade Association conference, where medtech leaders come together. With me on the call is our CFO, Patrick Bach. I will take you through the quarter's strategic highlights, then hand over to Patrick for a closer look at the numbers before we open the line for your questions. Today's title, Accelerating Performance, validates our partnership model and captures exactly where we landed: a very strong third quarter, following a solid second. With growth in our licensed business flowing straight through to earnings and cash flow. So let's dive straight into the quarter. Let's start with some high-level numbers. We are very pleased to report third quarter net sales growth, excluding currency, of 24%, with total revenue of 58 MSEK, up from 48 MSEK a year ago. License revenues grew 40%, excluding currency, driven mainly by the BD partnership, where we saw the strongest growth in a decade. Adjusted EBITDA came in at 20 MSEK, corresponding to a margin of 34%. It is a clear demonstration of the operating leverage of the license business, with top-line growth flowing through to earnings and cash flow. Strategically, it was a quarter of real progress. BD is performing strongly across both established and newly launched markets. Market-based revenues from Zimmer Biomet are gaining momentum, and we made meaningful headway in our partner dialogues, with the strongest engagement in orthopedics. Let me take these one at a time. Let's turn to the BD partnership, which was a key contributor to the performance this quarter. Revenues from BD grew 30%, excluding currency, and the growth in the partnership is the strongest we have seen in a decade, coming both from contract manufacturing as well as royalties on market sales. What makes this particularly encouraging is understanding why this is happening. The long-standing markets keep performing well, and the markets launched over the past year, such as the Nordics, Poland, and parts of the Middle East, are now generating increasing demand. That reflects the cumulative impact of our cooperation and development efforts with BD.
The regulatory approvals, the technology training across the regions, and the continued commercialization and market development activities in Europe. Increasing volumes in these newer markets validate the work behind those market transitions, and they support our confidence in the long-term expansion of the partnership.
It's also worth remembering the foundation. This is a partnership that goes back to the early 1990s, with more than 245 million Bactiguard coated Foley catheters to date, and with BD having the exclusive global rights outside of China since late 2023. We renewed this agreement for the long term as recently as earlier this year, and there is still plenty of opportunity for us to grow together. Now to Zimmer Biomet. Under the amended agreement signed late 2025, our royalties are now more closely tied to underlying market performance. This quarter, we saw that start to come through, and in addition to fixed fees, we had double-digit growth in royalties from in-market product sales. Our partnership with a global leader in orthopedics has clear long-term potential as the use of and demand for Bactiguard-coated implants grows. We also continue to execute on our regulatory programs and on our scientific publication and visibility strategy. In September, we presented new data at two leading conferences, including a joint publication with Zimmer Biomet comparing silver-containing surface technologies, which shows that silver is not the same as silver, and the differentiation of our noble metal technology, which has no market equivalent. We also presented Bactiguard data on the durability of the coating. The relevance of all this data extends beyond the trauma implant and our Zimmer Biomet relationship, and is something we can leverage for the technology across all of our partnerships.
Also during the quarter, an independent study from the University of Bari Aldo Moro in Italy was published.
These results further confirmed promising infection prevention outcomes with the ZNN Bactiguard nail in high-risk fracture patients. The combination of a differentiated mechanism, demonstrated durability, and good clinical outcomes creates trust in the Bactiguard noble metal technology, both from clinicians and hospitals deciding which trauma nail products to purchase, but also for potential new partners.
Now let's turn to business development. This slide is a snapshot across the therapeutic areas and the various categories of our partnerships, including material transfer agreements, application development, exclusivity, and license partnerships. Given the expected lead times associated with partnership and product development in medtech, we continue to take a long-term perspective on these opportunities. Having said that, during the quarter, we deepened our engagement and made meaningful headway in various dialogues, which further reinforces our optimism for future product development. Orthopedics is where partner engagement is strongest. This reflects the well-recognized need for infection prevention in implant surgery, and for payers who are increasingly focused on the economic burden of infections.
We are also increasingly a strategic partner beyond the noble metal technology itself. Over the past two years, we have expanded our regulatory expertise and our direct dialogue with authorities, including the US FDA, to help partners through an efficient product approval process, and we continue to strengthen the scientific evidence behind the technology. That growing involvement shows how the value we bring extends beyond the coating. As always in a licensed business, discussions like these take time to mature into signed agreements, and our focus remains firmly on advancing them. Now let's turn to wound management. After a very strong second quarter, wound management had a softer third quarter. Revenues were 14 MSEK, down just under 9% excluding currency, mainly reflecting product order phasing and the inherent variability from quarter to quarter. The longer-term picture is therefore more relevant, and wound management grew approximately 14% organically over the first nine months, led by Hydrocyn aqua. We continue to invest in ensuring product availability, including the MDR process and our operations in Penang, Malaysia. And as we've said before, we continue to expect double-digit growth from the wound management portfolio. With that, over to Patrick for a closer look at the numbers.